피부진균증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.6%로 성장할 전망이며, 185억 9,000만 달러로 성장이 예측됩니다. 예측 기간 동안 예상되는 성장의 원동력은 고령화 인구 증가, 약물 내성 진균 증가, 천연 및 유기 항진균 제품에 대한 수요 증가, 생명공학 및 항진균 연구의 진보, 개발도상 지역에서 헬스케어 접근 개선 등의 요인입니다. 이 기간에 예상되는 주요 동향으로는 새로운 항진균제 개발, 신속 진단법의 진보, 피부과학의 인공지능 통합, 나노기술을 이용한 항진균 치료법의 발전, 미생물 기반 치료법의 혁신 등이 있습니다.
진균 감염의 유병률 증가는 향후 수년간 피부진균증 시장의 성장을 가속할 것으로 예측됩니다. 진균 감염은 진균이 피부, 손톱, 모발, 내장 등에 감염됨으로써 발병하며 다양한 건강 합병증을 일으킵니다. 광역항생제 과다 사용은 자연 마이크로바이옴을 파괴하고 진균이 번식해 감염병을 일으키는 환경을 만들어 냅니다. 이러한 혼란은 신체의 자연스러운 방어 기구를 약화시켜 기회균 감염에 걸리기 쉽게 합니다. 피부진균증 피부사상균, 효모, 곰팡이에 의해 야기되는 진균증은 다양한 조직에 영향을 미쳐 표면 감염과 전신 감염을 모두 일으킵니다. 예를 들어 2023년 11월 영국 공중보건기구인 UK Health Security Agency는 전 세계 추정으로는 연간 650만 명의 침습성 진균 감염병이 발생해 약 380만 명이 사망하고 250만 명이 이들 감염병에 직접 기인하고 있다고 보고했습니다. 그 결과 진균 감염증의 유병률 상승이 피부 진균증 시장의 성장을 촉진하고 있습니다.
경구약에 대한 수요 증가가 향후 피부진균증 시장의 확대에 기여할 것으로 예측되고 있습니다. 경구약이란 알약, 캡슐제, 액제 등의 형태로 입으로 복용하는 약제를 말하며 소화기관에서 흡수됩니다. 주사나 다른 배달 방법에 비해 편의성이 높고 효과도 높기 때문에 경구약이 다양한 질환의 치료 선택지로 선호되고 있습니다. 피부진균증 치료의 장점은 전신성 항진균제가 혈액순환을 통해 감염된 피부, 모발, 손톱에 침투해 외용약에 비해 더 깊고 더 오래 치료가 지속된다는 것입니다. 예를 들어, 2022년 10월 미국의 정부기관인 질병대책예방센터는 경구항바이러스제 조제 수가 57% 증가하여 2022년 4월 24일부터 5월 21일 사이에 10만 명당 643명이었던 것이 2022년 7월 31일부터 8월 28일 사이에 10만 명당 1,012명으로 증가하였다고 보고하고 있습니다. 그 결과 경구약에 대한 수요의 증가가 피부 진균증 시장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 피부진균증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 피부진균증 시장 : 성장률 분석
- 세계의 피부진균증 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 피부진균증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 피부진균증 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 피부진균증 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 코르티코스테로이드
- 코르티코스테로이드 절약약
- 면역억제제
- 면역조절제
- 항진균제
- 기타
- 세계의 피부진균증 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 비경구
- 국소
- 기타
- 세계의 피부진균증 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 기타
- 세계의 피부진균증 시장 : 코르티코스테로이드별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 국소 코르티코스테로이드
- 경구 코르티코스테로이드
- 주사용 코르티코스테로이드
- 세계의 피부진균증 시장 : 코르티코스테로이드 절약약별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 타크로리무스
- 피메크로리무스
- 세계의 피부진균증 시장 : 면역 억제제별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 메토트렉세이트
- 아자티오프린
- 시클로포스파미드
- 세계의 피부진균증 시장 : 면역조절제별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 인터페론-감마
- 탈리도마이드
- 세계의 피부진균증 시장 : 항진균제별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 국소 항진균제
- 경구 항진균제
- 전신성 항진균제
- 세계의 피부진균증 시장 : 기타 의약품별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항히스타민제
- 항균제
제7장 지역별 및 국가별 분석
- 세계의 피부진균증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 피부진균증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 피부진균증 시장 : 경쟁 구도
- 피부진균증 시장 : 기업 프로파일
- Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
- Saphnix Life Sciences : 개요, 제품 및 서비스, 전략 및 재무 분석
- MITS Healthcare Private Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
- Weefsel Pharma : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- AdvaCare Pharma
- Associated BIoTech
- Healthy Life Pharma Private Limited
- Blueberry Therapeutics Ltd.
- Livealth Biopharma Pvt. Ltd.
- LGM Pharma
- SiNi Pharma Pvt. Ltd.
- Joshi Agrochem Pharma Private Limited
- Wellona Pharma
- Abiba Pharmacia Pvt. Ltd.
- Vee Excel Drugs & Pharmaceuticals Pvt. Ltd.
- Femcorp Pharma
- Lexicare Pharma Pvt. Ltd.
- Glamris Dermacare
- Henin Lukinz
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 피부진균증 시장(2029년) : 새로운 기회를 제공하는 국가
- 피부진균증 시장(2029년) : 새로운 기회를 제공하는 부문
- 피부진균증 시장(2029년) : 성장 전략
제36장 부록
AJY
Dermatomycoses refer to a group of fungal infections that affect the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often result in symptoms such as itching, scaling, redness, and skin inflammation, negatively impacting skin health. The primary aim of treatment is to eradicate the fungal infection, relieve symptoms, and prevent recurrence through the use of antifungal medications, proper hygiene, and consistent skin care practices.
The main drug categories for treating dermatomycoses include corticosteroids, corticosteroid-sparing agents, immunosuppressives, immunomodulators, antifungals, and others. Corticosteroids are anti-inflammatory drugs that help reduce swelling, redness, and itching in skin conditions. These medications can be administered in various forms, such as oral, parenteral, topical, and others, and are used by different end-users, including hospitals, specialty clinics, and others.
The dermatomycoses market research report is one of a series of new reports from The Business Research Company that provides dermatomycoses market statistics, including the dermatomycoses industry global market size, regional shares, competitors with the dermatomycoses market share, detailed dermatomycoses market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomycoses industry. This dermatomycoses market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dermatomycoses market size has grown strongly in recent years. It will grow from $14.12 billion in 2024 to $14.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to advancements in antifungal therapies, the rising prevalence of fungal infections, growing awareness about skin health, improvements in diagnostic techniques, and the expansion of over-the-counter antifungal products.
The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $18.59 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth during the forecast period is driven by factors such as the rising aging population, the increasing prevalence of drug-resistant fungal strains, the growing demand for natural and organic antifungal products, advancements in biotechnology and antifungal research, and improved healthcare access in developing regions. Key trends expected in this period include the development of new antifungal drugs, progress in rapid diagnostic methods, the integration of artificial intelligence in dermatology, advancements in nanotechnology-based antifungal treatments, and innovations in microbiome-based therapies.
The increasing prevalence of fungal infections is expected to drive the growth of the dermatomycoses market in the coming years. Fungal infections occur when fungi infect the skin, nails, hair, or internal organs, leading to various health complications. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, creating an environment that allows fungi to thrive and cause infections. This disruption weakens the body's natural defense mechanisms, making individuals more susceptible to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, are responsible for fungal diseases, affecting different tissues and leading to both superficial and systemic infections. For example, in November 2023, the UK Health Security Agency, a UK-based public health organization, reported that global estimates indicate an annual occurrence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 million directly attributed to these infections. As a result, the rising prevalence of fungal infections is fueling the growth of the dermatomycoses market.
The increasing demand for oral drugs is anticipated to contribute to the expansion of the dermatomycoses market in the future. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The preference for oral drugs is growing as they offer greater convenience and effectiveness compared to injections or other delivery methods, making them a favored treatment option for various conditions. Dermatomycoses treatment benefits from oral drugs by enabling systemic antifungal agents to penetrate infected skin, hair, or nails through blood circulation, ensuring deeper and longer-lasting treatment compared to topical applications. For example, in October 2022, the Centers for Disease Control and Prevention, a US-based government agency, reported a 57% increase in oral antiviral dispensing, rising from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Consequently, the growing demand for oral drugs is driving the dermatomycoses market forward.
Leading companies in the dermatomycoses market are concentrating on investigational new drug candidates to enhance onychomycosis treatment and improve therapeutic efficacy. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical trials to assess its safety, effectiveness, and potential for regulatory approval before becoming an authorized treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its investigational new drug VTR-297, intended for the treatment of onychomycosis. VTR-297 is distinguished by its histone deacetylase (HDAC) inhibitor properties, setting it apart from conventional antifungal treatments. This approach targets the root cause of fungal growth, exhibiting strong antifungal activity against dermatophytes and other fungi. The novel mechanism of action has the potential to deliver faster and more effective treatment outcomes while reducing the risk of infection recurrence, addressing a critical unmet need in onychomycosis treatment.
Major players in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz.
North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycoses report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dermatomycoses market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dermatomycoses market consists of sales of barrier creams or protective skin creams, medicated soaps and body washes, and cryotherapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dermatomycoses Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dermatomycoses market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dermatomycoses ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomycoses market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drugs: Corticosteroids; Corticosteroid-Sparing Agents; Immunosuppressive; Immunomodulator; Antifungals; Other Drugs
- 2) By Route Of Administration: Oral; Parenteral; Topical; Other Routes Of Administration
- 3) By End-User: Hospitals; Specialty Clinics; Other End-Users
- Sub Segments:
- 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
- 2) By Corticosteroid-Sparing Agents: Tacrolimus; Pimecrolimus
- 3) By Immunosuppressive: Methotrexate; Azathioprine; Cyclophosphamide
- 4) By Immunomodulator: Interferon-Gamma; Thalidomide
- 5) By Antifungals: Topical Antifungals; Oral Antifungals; Systemic Antifungals
- 6) By Other Drugs: Antihistamines; Antibacterial Agents
- Companies Mentioned: Pfizer Inc.; Bayer AG; Saphnix Life Sciences; MITS Healthcare Private Limited; Weefsel Pharma
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dermatomycoses Market Characteristics
3. Dermatomycoses Market Trends And Strategies
4. Dermatomycoses Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dermatomycoses Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dermatomycoses PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dermatomycoses Market Growth Rate Analysis
- 5.4. Global Dermatomycoses Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dermatomycoses Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dermatomycoses Total Addressable Market (TAM)
6. Dermatomycoses Market Segmentation
- 6.1. Global Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Corticosteroid-Sparing Agents
- Immunosuppressive
- Immunomodulator
- Antifungals
- Other Drugs
- 6.2. Global Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Topical
- Other Routes Of Administration
- 6.3. Global Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Other End-Users
- 6.4. Global Dermatomycoses Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Topical Corticosteroids
- Oral Corticosteroids
- Injectable Corticosteroids
- 6.5. Global Dermatomycoses Market, Sub-Segmentation Of Corticosteroid-Sparing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tacrolimus
- Pimecrolimus
- 6.6. Global Dermatomycoses Market, Sub-Segmentation Of Immunosuppressive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Methotrexate
- Azathioprine
- Cyclophosphamide
- 6.7. Global Dermatomycoses Market, Sub-Segmentation Of Immunomodulator, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Interferon-Gamma
- Thalidomide
- 6.8. Global Dermatomycoses Market, Sub-Segmentation Of Antifungals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Topical Antifungals
- Oral Antifungals
- Systemic Antifungals
- 6.9. Global Dermatomycoses Market, Sub-Segmentation Of Other Drugs, By Tyepe, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antihistamines
- Antibacterial Agents
7. Dermatomycoses Market Regional And Country Analysis
- 7.1. Global Dermatomycoses Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dermatomycoses Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dermatomycoses Market
- 8.1. Asia-Pacific Dermatomycoses Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dermatomycoses Market
- 9.1. China Dermatomycoses Market Overview
- 9.2. China Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dermatomycoses Market
- 10.1. India Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dermatomycoses Market
- 11.1. Japan Dermatomycoses Market Overview
- 11.2. Japan Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dermatomycoses Market
- 12.1. Australia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dermatomycoses Market
- 13.1. Indonesia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dermatomycoses Market
- 14.1. South Korea Dermatomycoses Market Overview
- 14.2. South Korea Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dermatomycoses Market
- 15.1. Western Europe Dermatomycoses Market Overview
- 15.2. Western Europe Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dermatomycoses Market
- 16.1. UK Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dermatomycoses Market
- 17.1. Germany Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dermatomycoses Market
- 18.1. France Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dermatomycoses Market
- 19.1. Italy Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dermatomycoses Market
- 20.1. Spain Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dermatomycoses Market
- 21.1. Eastern Europe Dermatomycoses Market Overview
- 21.2. Eastern Europe Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dermatomycoses Market
- 22.1. Russia Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dermatomycoses Market
- 23.1. North America Dermatomycoses Market Overview
- 23.2. North America Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dermatomycoses Market
- 24.1. USA Dermatomycoses Market Overview
- 24.2. USA Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dermatomycoses Market
- 25.1. Canada Dermatomycoses Market Overview
- 25.2. Canada Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dermatomycoses Market
- 26.1. South America Dermatomycoses Market Overview
- 26.2. South America Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dermatomycoses Market
- 27.1. Brazil Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dermatomycoses Market
- 28.1. Middle East Dermatomycoses Market Overview
- 28.2. Middle East Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dermatomycoses Market
- 29.1. Africa Dermatomycoses Market Overview
- 29.2. Africa Dermatomycoses Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dermatomycoses Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dermatomycoses Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dermatomycoses Market Competitive Landscape And Company Profiles
- 30.1. Dermatomycoses Market Competitive Landscape
- 30.2. Dermatomycoses Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Saphnix Life Sciences Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. MITS Healthcare Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Weefsel Pharma Overview, Products and Services, Strategy and Financial Analysis
31. Dermatomycoses Market Other Major And Innovative Companies
- 31.1. AdvaCare Pharma
- 31.2. Associated Biotech
- 31.3. Healthy Life Pharma Private Limited
- 31.4. Blueberry Therapeutics Ltd.
- 31.5. Livealth Biopharma Pvt. Ltd.
- 31.6. LGM Pharma
- 31.7. SiNi Pharma Pvt. Ltd.
- 31.8. Joshi Agrochem Pharma Private Limited
- 31.9. Wellona Pharma
- 31.10. Abiba Pharmacia Pvt. Ltd.
- 31.11. Vee Excel Drugs & Pharmaceuticals Pvt. Ltd.
- 31.12. Femcorp Pharma
- 31.13. Lexicare Pharma Pvt. Ltd.
- 31.14. Glamris Dermacare
- 31.15. Henin Lukinz
32. Global Dermatomycoses Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dermatomycoses Market
34. Recent Developments In The Dermatomycoses Market
35. Dermatomycoses Market High Potential Countries, Segments and Strategies
- 35.1 Dermatomycoses Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dermatomycoses Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dermatomycoses Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
